hiv-1 wt

HIV-1 inhibitor-54 is a potent inhibitor of WT HIV-1 (strain IIIB) in MT-4 cells, demonstrating anti-HIV activity with an EC50 of 32 nM. [HIV-1 inhibitor-54 can be used to study viral infections.]

HIV-1 Inhibitor-61 (2c) serves as a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an EC50 value of 0.07 nM in NL4-3 wt MT-4 cells [1].

HIV-1 Inhibitor-59 (Compound I-5b) effectively inhibits both wild-type and mutant strains of HIV-1, with EC50 values ranging from 5.62 to 171 nM. Additionally, it demonstrates moderate inhibitory activity against the reverse transcriptase (RT) enzyme, with IC50 values between 0.094 and 12.0 μM [1].

HIV-1 Inhibitor-49, a HEPT analog, is an orally active non-nucleoside reverse transcriptase inhibitor with potent activity against HIV-1, demonstrating an IC 50 of 30 nM. It features an excellent pharmacokinetic profile and has shown to be potentially safe without acute toxicity in mouse models.

HIV-1 inhibitor-21 (compound 9b) is a potent inhibitor of HIV-1 non-nucleoside reverse transcriptase (RT) with an IC50 of 0.55 μM. It inhibits both wild-type HIV-1 (EC50: 12.7 nM) and mutant virus strain K103N (EC50: 10.4 nM), demonstrating relatively low cytotoxicity (CC50 for MT-4: 10.2 μM).

HIV-1 inhibitor-28 is a potent and selective HIV-1 inhibitor with EC50=58 nM for wild-type HIV-1, IC50=3.37 μM for wild-type HIV-1 reverse transcription, and relatively low toxicity to MT-4 cells with CC50= 38.6 μM. HIV-1 inhibitor-28 can be used in AIDS research.

HIV-1 inhibitor-16 (compound 7a) is a potent HIV-1 inhibitor with an EC50 of 1.3 nM against wild-type HIV-1, and exhibits inhibitory activity against HIV-1 K103N, E138K, Y181C, and L100I strains with EC50s of 5.4 nM, 9.2 nM, 22 nM, and 35 nM, respectively. It demonstrates good solubility, hepatic microsomal stability, and lacks significant CYP enzyme inhibitory activity or acute toxicity.

HIV-1 inhibitor-9 exhibits potent inhibition activity at low nanomolar concentrations against both the wild-type (WT) HIV-1 strain and multiple strains that have developed resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Islatravir (MK-8591) is an effective anti-HIV-1 agent. It acts as a nucleoside reverse transcriptase inhibitor (EC50s: 0.068 nM, 3.1 nM, and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively).

HIV-1 inhibitor-15 (compound 9d) is a potent, broad-spectrum inhibitor targeting HIV-1, with EC50 values of 1.7 nM against HIV-1 WT, 4 nM against L100I, 2 nM against K103N, 6 nM against Y181C, and 9 nM against E138K. It exhibits high efficacy, favorable solubility, safety profiles, and oral bioavailability [1].

HIV-1 inhibitor-52 is a powerful inhibitor of a broad spectrum of HIV-1 activities, demonstrating effectiveness with EC50 values ranging from 1.6 nM to 6.4 nM against various strains, including [WT HIV-1], [HIV-1 V370A], [HIV-1 ΔV370], [HIV-1 V362I V370A], [HIV-1 T332S V362I prR41G], [HIV-1 A326T V362I V370A], and [HIV-1 R361K V362I L363M].

CI-39, a natural antiviral product, serves as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting wild type HIV-1. It exhibits an effective concentration (EC50) of 3.40 µM against the virus, while its cytotoxic concentration (CC50) exceeds 30 µM. This compound notably impedes HIV-1 reverse transcriptase (RT) DNA polymerase and ribonuclease H activities[1].

HIV-1 inhibitor-40 (Compound 4ab), an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 1.9 nM, exhibits no significant acute toxicity in vivo and functions as a highly sensitive inhibitor of the orexin receptor antagonist CYP.

HIV-1inhibitor-74 (compound 10c) is a potent inhibitor of HIV-1, displaying an EC50 of 0.0047 µM against HIV-1IIIB. It exhibits cytotoxic properties and effectively inhibits the activity of WTHIV-1RT with an IC50 of 0.134 µM. Additionally, HIV-1inhibitor-74 demonstrates broad-spectrum anti-HIV-1 activity.

GSK3532795 is a potent, orally active, second-generation HIV-1 maturation inhibitor (EC50s: 10.2, 1.9, 2.7, and 13 nM for HIV-1 WT(human serum), HIV-1 WT, HIV-1 V370A, and HIV-1 ΔV370).

HIV-1 inhibitor-23 is a highly potent inhibitor of HIV-1 non-nucleoside reverse transcriptase, acting on both wild-type HIV-1 (EC50: 24.9 nM) and mutant strain K103N (EC50: 10.4 nM). microsomal stability in vitro.

HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM and a CC50 of 18 μM in MT-4 cells, and can be used in the study of AIDS.

ZLM-66 is a doravirine analogue and a potent inhibitor of non-nucleoside reverse transcriptases (NNRTIs), acting on wild-type HIV-1 reverse transcriptase (IC50: 41 nM), wild-type HIV-1 (EC50: 13 nM) and cIAP1 (EC50: 0.32 nM). ZLM-66 can be used in AIDS research.

HIV-1 Inhibitor-58 (Compound 10c) is a non-nucleoside reverse transcriptase inhibitor with broad-spectrum antiviral properties, effective against both wild-type strain IIIB and NNRTI-resistant strains like K103N and E138K in MT-4 cells at an EC50 of less than 50 nM. Additionally, it inhibits CYP2C9 and CYP2C19 with IC50 values of 2.06 μM and 1.91 μM, respectively. This compound is utilized in HIV infection research [1].

HIV-1 inhibitor-32 is a potent inhibitor of HIV-1 that acts on wild-type HIV (IC50: 34 nM) and can be used in AIDS research.

HIV-1 inhibitor-13 is an orally active HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an IC50 value of 0.14 μM against HIV-1 RT. HIV-1 inhibitor-13 is active against HIV-1 resistant strains (EC50: 2.85-18.0 nM).

HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor, with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells, making it useful for AIDS research.

HIV-1 inhibitor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets HIV-1 reverse transcriptase (IC50 = 50 nM). HIV-1 inhibitor-50 shows significant antiviral activity, with EC50s of 2.22-53.3nM against HIV-1 IIIB and its mutant strains.

Darunavir Ethanolate (UIC 94017) is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.